Phase 2 N=39 Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Colon Cancer · Rectal Cancer
Primary: Incidence of Complete Resection — 13 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
Spinal Cord Injury
Primary: Inspiratory Respiratory Muscle Strength — 82.35; 79.19; 85.31; 91.69 cmH2O
N/A N=25 Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant
Leukemia
Primary: Percentage of Participants With Relapse-free Survival (RFS) — 52 percentage of participants
Phase 3 N=1,106 Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
Diphtheria · Tetanus · Whooping Cough
Primary: Summary of Diphtheria and Tetanus Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV Hep B-PRP T Vaccine or…
Phase 4 N=41 NasoNeb Delivery of an Intranasal Steroid
Perennial Allergic Rhinitis
Primary: Change in Nasal Peak Inspiratory Flow (NPIF) — 36.41; 18.71 liters/min
Phase 4 N=61 Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation
Respiratory Distress Syndrome, Newborn
Primary: Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 > 0.60 to Maintain Target SpO2, or Second Dose of…
Phase 2 N=47 Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Stem Cell Transplantation · Leukemia
Primary: Number of Participants With Grade 4 Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) Plerixafor — 1; 4; 7; 4 participants
Phase 2 N=101 Usefulness of Selegiline as an Aid to Quit Smoking - 1
Tobacco Use Cessation
Primary: 7 Day Point Prevalence of Cigarette Abstinence — 6; 8 participants
Phase 2 N=97 Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
Glioblastoma Multiforme
Primary: Survival — 17.2 months — p=>.1
Phase 3 N=2,705 Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment — -0.70; -0.82; 0.09; -0.58 % of HbA1c — p=<0.0001
Phase 2 N=24 Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers
Asthma
Primary: Baseline Concentration (C0) of Labeled Epinephrine Total Epinephrine — 9.3; 8.9; 7.8 pg/mL
N/A N=31 Handgrip Exercise for Arteriovenous Fistula Maturation
Chronic Kidney Disease
Primary: Venous Diameter. — 5.78; 6.42 mm
Phase 4 N=31 Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients
Poor Quality Sleep
Primary: Sleep Efficiency — 70.0; 65.8 percentage of sleep
N/A N=459 SUPPORT FOR FRAIL ELDERLY PERSONS - From Prevention to Palliation
Frail Elderly Persons
Primary: Dependence in Two or More Activities of Daily Living (ADL) — 35; 26; 44 participants — p=<0.05
Phase 2 N=148 A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Primary: Best Tumor Response (Core) — 0; 1; 49; 49 participants